A compassionate access protocol to assess the safety of xolair (omalizumab) in patients (greater than or equal to 6 years old) with severe allergic asthma who remain symptomatic despite optimal therapy
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Novartis
- 23 May 2012 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 27 Oct 2011 Planned End Date changed from 1 Dec 2008 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 03 Apr 2008 New trial record.